Net Worth Advisory Group Buys 24 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Net Worth Advisory Group raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the first quarter, Holdings Channel reports. The fund owned 1,708 shares of the biopharmaceutical company’s stock after purchasing an additional 24 shares during the quarter. Net Worth Advisory Group’s holdings in Regeneron Pharmaceuticals were worth $1,083,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the business. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $25,000. Rakuten Securities Inc. raised its holdings in Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. Finally, Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $36,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $518.60 on Thursday. The company has a fifty day simple moving average of $564.76 and a 200 day simple moving average of $653.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $55.99 billion, a P/E ratio of 13.55, a PEG ratio of 2.34 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the business posted $9.55 EPS. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.96%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on REGN shares. Guggenheim restated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating for the company in a report on Monday, June 2nd. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a report on Monday, June 2nd. Finally, Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.